NR AWFJ
AU Ghetti,B.; Kepe,V.; Bresjanac,M.; Huang,S.; Small,G.W.; Satyamurthy,N.; Farlow,M.R.; Epperson,F.; Repovs,G.; Smid,L.M.; Popovic,M.; Petric,A.; Phelps,M.E.; Barrio,J.R.
TI Visualization of PrP-amyloid disease with (F-18)FDDNP in Gerstmann-Sträussler-Scheinker (GSS)
QU International Conference - Prion 2006: Strategies, advances and trends towards protection of society - 3.10.-6.10.2006, Torino, Italy, Lingotto Conference Centre - Poster sessions DIA-17
PT Konferenz-Poster
AB Positron emission tomography was used in conjunction with 2-(1-{6-[(2-[F-18]fluoroethyl)(methyl) amino]-2-naphthyl}ethylidene) malononitrile; [F-18]FDDNP) for visualization of pathology in the living brain of GSS patients. Five subjects with the F198S and P102L mutations in PRNP and five controls were scanned. Logan graphical analysis with arterialized venous blood input function was applied for quantitative data analysis. The [F-18]FDDNP distribution volume (DV) parametric images were generated and the region-of-interest (R0I) analysis was performed. In vivo results were compared with the known brain pathology pattern. [F-18]FDDNP DV parametric images of GSS subjects show the following results: (1) two symptomatic F198S cases (GSS1 and GSS4) have significantly increased DV values in the basal ganglia and cerebellum (GSS1) and in BG, thalamus and CB (GSS4); neocortical regions have lower DV values compared to those observed in CB, BG, or thalamus; (2) of two pre-symptomatic subjects (GSS2 and GSS5) the older one GSS2 (45 y) has increased BG and thalamus DV values, comparable to the symptomatic subjects and significantly higher than in controls, and cerebellar DV values comparable to controls; the younger presymptomatic subject GSS5 (30 y) has no pathology, with DV values within the limits observed in controls for all brain areas; (3) the P102L subject (GSS3) shows qualitatively similar, but milder, pattern of [F-18]FDDNP accumulation in subcortical areas as the two asymptomatic F198S cases. All symptomatic cases show decreased glucose utilization in affected areas. We have demonstrated feasibility of in vivo detection of prion pathology using [F-18]FDDNP, a probe with affinity for amyloidlike protein aggregates.
AD B. Ghetti, M.R. Farlow, F. Epperson: Department of Pathology, Indiana University, Indianapolis, USA; V. Kepe, S. Huang, G.W. Small, N. Satyamurthy, M.E. Phelps, J.R. Barrio: Department Medical and Molecular Pharmacology, UCLA, Los Angeles, USA; M. Bresjanac, G. Repovs, L.M. Smid, M. Popovic, A. Petric: Institute of Pathophysiology and Department of Chemistry and Biochemistry, University of Ljubljana, Ljubljana, Slovenia
SP englisch
PO Italien